HomeAI · summaries
Storia in 20 fonti
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly…
- ·
healio.com
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor,…
